Mounjaro

Blood Sugar Management

Mounjaro is primarily used to help manage blood sugar (glucose) levels in adults with type 2 diabetes. It works by mimicking hormones that help the body release insulin and reduce the amount of sugar the liver makes. This helps lower hemoglobin A1c, which is a measure of average blood sugar over time.

Usage with Lifestyle Changes

This medication is not meant to be used as a standalone treatment. It is prescribed as part of a comprehensive management plan that includes:

• A healthy, calorie-controlled diet
• Regular physical activity and exercise
• Routine blood sugar monitoring

Limitations of Use

Mounjaro has specific limitations regarding who should use it and for what conditions:

• It is not used to treat type 1 diabetes.
• It is not intended for people who have had pancreatitis in the past.
• It is not used to treat diabetic ketoacidosis, a serious complication of diabetes.

Weight Management Context

While Mounjaro is specifically FDA-approved for the treatment of type 2 diabetes, the active ingredient (tirzepatide) is known to cause weight loss. A different brand name of the same medication is specifically approved for chronic weight management, but Mounjaro itself is indicated for blood sugar control.

Mechanism of Action

Mounjaro contains the active ingredient tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. These are hormones naturally produced in the body, often called incretins, that play a key role in managing blood sugar and appetite.

Blood Sugar Regulation

The medication helps control blood sugar through two primary actions in the pancreas and liver:

• Insulin Release: It stimulates the pancreas to release more insulin after eating, which helps the body move sugar from the bloodstream into cells for energy.
• Glucagon Control: It reduces the amount of glucagon the liver produces, which prevents excess sugar from being released into the blood.

Digestion and Appetite

Mounjaro also affects how the body processes food and signals hunger to the brain:

• Slower Gastric Emptying: It slows down the speed at which food leaves the stomach. This helps prevent blood sugar spikes after meals and contributes to a feeling of fullness.
• Appetite Suppression: By mimicking natural hormones, the medication acts on receptors in the brain that regulate hunger and satiety, which can lead to decreased food intake.

Common Side Effects

The most frequently reported side effects of Mounjaro affect the digestive system. These symptoms often occur when the dose is first started or increased.

• Nausea and vomiting
• Diarrhea
• Decreased appetite
• Constipation
• Indigestion or upset stomach
• Stomach pain
• Injection site reactions, such as redness or swelling

Serious Side Effects

While less common, Mounjaro can cause serious side effects that require prompt medical attention. These include:

• Pancreatitis: Severe pain in the stomach area that may spread to the back.
• Gallbladder problems: Symptoms such as upper stomach pain, fever, or yellowing of the skin or eyes.
• Kidney issues: Severe digestive side effects can lead to dehydration, which may cause kidney injury.
• Vision changes: New or worsening eyesight problems.
• Severe allergic reactions: Swelling of the face, lips, or throat, difficulty breathing, or a severe rash.
• Low blood sugar: Increased risk of hypoglycemia when used with other diabetes medications like insulin.

Mounjaro may also cause thyroid tumors. Contact a doctor if you notice a lump or swelling in the neck, hoarseness, or trouble swallowing.

Boxed Warning: Thyroid C-cell Tumors

In animal studies, tirzepatide caused thyroid C-cell tumors. It is not known whether Mounjaro causes these tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in humans. This medication is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis

There have been reports of pancreatitis (inflammation of the pancreas) in patients treated with Mounjaro. The medication has not been studied in patients with a history of pancreatitis. If pancreatitis is suspected, the drug should be discontinued immediately and not restarted if the diagnosis is confirmed.

Severe Gastrointestinal Disease

Mounjaro is associated with gastrointestinal adverse reactions, which can sometimes be severe. Because it has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, its use is not recommended in these populations.

Kidney Impairment

Gastrointestinal side effects such as nausea, vomiting, and diarrhea may lead to dehydration, which can cause acute kidney injury. Monitoring kidney function is recommended, especially when starting treatment or increasing the dosage in patients reporting severe gastrointestinal reactions.

Hypoglycemia

When used in combination with an insulin secretagogue, such as a sulfonylurea, or insulin, there is an increased risk of hypoglycemia (low blood sugar). A reduction in the dose of the accompanying medication may be required to lower this risk.

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. If a reaction occurs, the medication must be stopped and medical attention sought immediately. It should not be used in patients with a known serious hypersensitivity to tirzepatide.

Diabetic Retinopathy

Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of this condition should be monitored for changes in vision during treatment.

Gallbladder Disease

Acute gallbladder disease, such as gallstones or inflammation of the gallbladder, has been observed in clinical trials. If gallbladder disease is suspected, diagnostic studies and appropriate medical follow-up are indicated.

Pregnancy and Oral Contraceptives

Mounjaro may reduce the effectiveness of oral contraceptives due to delayed gastric emptying. Patients using oral birth control may be advised to switch to a non-oral method or add a barrier method for four weeks after starting the drug and for four weeks after each dose increase.

Pregnancy

There is limited information regarding the safety of Mounjaro in pregnant individuals. In animal studies, the medication was associated with potential risks to the developing fetus, including lower birth weight and physical abnormalities. Because of these findings, healthcare providers typically advise against using this medication during pregnancy. If you become pregnant while taking this medication, you should contact your healthcare provider immediately.

Birth Control Considerations

Mounjaro may reduce the effectiveness of oral contraceptive pills (birth control pills). This interaction is most likely to occur when you first start the medication or when your dose is increased. To prevent unintended pregnancy, healthcare providers may recommend the following for at least four weeks after starting the drug and for four weeks after each dose increase:

• Switching to a non-oral form of birth control, such as a patch, injection, or vaginal ring.
• Adding a barrier method, such as condoms, in addition to your regular birth control pills.

Breastfeeding

It is currently unknown whether Mounjaro passes into human breast milk or if it could affect a nursing infant. Because the risks are not well-defined, it is important to discuss the potential benefits and risks with a healthcare professional before breastfeeding while using this medication.

Dosage Forms

Mounjaro is administered as an injection under the skin. It is available in the following form:

• Prefilled pen: A disposable device that contains the medication solution for injection.

The medication is a clear liquid solution. Prefilled pens are designed for use and then disposal.

FDA Approval and Indications

Mounjaro (tirzepatide) received FDA approval in May 2022. It is specifically approved for use in adults with type 2 diabetes mellitus to help manage blood sugar levels when used in combination with diet and exercise. It has not been studied in patients with a history of pancreatitis and is not indicated for use in patients with type 1 diabetes mellitus.

Boxed Warning

The prescribing information for Mounjaro contains a boxed warning regarding the risk of thyroid C-cell tumors. In animal studies, tirzepatide caused thyroid C-cell tumors in rats and mice. It is currently unknown if Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.

Due to this risk, Mounjaro is contraindicated in patients with:

• A personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Regulatory Actions

The FDA oversees the marketing and distribution of Mounjaro. The agency has issued warning letters to the manufacturer regarding promotional materials that were found to be misleading. These communications highlighted concerns that certain advertisements omitted important risk information or made claims about the drug's benefits that were not supported by clinical evidence.

How Mounjaro Affects Weight

Mounjaro contains tirzepatide, a medication that mimics two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones play a role in regulating blood sugar and appetite. By activating these hormone receptors, the drug slows down the rate at which the stomach empties and signals the brain to feel full sooner, which often results in weight loss.

FDA Approval and Off-Label Use

Mounjaro is currently FDA-approved to treat type 2 diabetes. However, because of its significant impact on body weight, healthcare providers may prescribe it off-label for weight management. A separate brand-name medication containing the same active ingredient, tirzepatide, is specifically approved for chronic weight management in adults with obesity or weight-related health conditions.

Weight Loss Results

In clinical studies, participants taking tirzepatide experienced substantial weight loss compared to those taking a placebo. The medication is intended to be used in combination with a reduced-calorie diet and increased physical activity. Results vary based on the dosage prescribed and individual health factors.

Potential Side Effects

The most common side effects associated with Mounjaro use for weight loss involve the digestive system. These may include:

• Nausea
• Diarrhea
• Decreased appetite
• Vomiting
• Constipation
• Indigestion